TherapeuticsMD, Inc. (TXMD) |
| 2.2 0.38 (20.88%) 06-12 16:00 |
| Open: | 1.885 |
| High: | 2.2 |
| Low: | 1.85 |
| Volume: | 258,327 |
| Market Cap: | 25(M) |
| PE Ratio: | 220 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.57 |
| Resistance 1: | 2.20 |
| Pivot price: | 2.02 |
| Support 1: | 1.95 |
| Support 2: | 1.80 |
| 52w High: | 2.95 |
| 52w Low: | 0.98 |
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
| EPS | 0.010 |
| Book Value | 2.320 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.290 |
| Profit Margin (%) | 5.34 |
| Operating Margin (%) | -28.45 |
| Return on Assets (ttm) | -3.0 |
| Return on Equity (ttm) | 0.3 |
Thu, 28 May 2026
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
Tue, 12 May 2026
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
Tue, 12 May 2026
Drug-royalty owner TherapeuticsMD turns Q1 profit, explores sale, merger options - Stock Titan
Sat, 14 Feb 2026
TXMD Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 11 Feb 2026
TherapeuticsMD, Inc. (TXMD) stock price prediction 2026–2030 - Bitget
Wed, 12 Nov 2025
TherapeuticsMD Announces Third Quarter 2025 Financial Results - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |